Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873666 | 0.81 | NOTUM (0.42) | NOTUMHTR2AHTR2CKMT2ADAO | |
| Hydroxyamine SCHEMBL9656514 | 0.76 | NOTUM (0.39) | NOTUMHTR2AHTR2CKMT2ADAO | |
| SCHEMBL11209350 | 0.74 | NOTUM (0.40) | NOTUMHTR2AHTR2C | |
| SCHEMBL10960778 | 0.74 | NOTUM (0.37) | NOTUMHTR2AHTR2C | |
| SCHEMBL11209343 | 0.74 | NOTUM (0.40) | NOTUMHTR2AHTR2C | |
| Benzoquinone SCHEMBL6697569 | 0.73 | NOTUM (0.42) | NOTUMHTR2AHTR2CDAO | |
| SCHEMBL3050639 | 0.69 | HTR2A (0.44) | NOTUMHTR2AHTR2CKMT2A | |
| SCHEMBL10917532 | 0.69 | HTR2A (0.39) | NOTUMHTR2AHTR2CKMT2A | |
| SCHEMBL3203383 | 0.67 | NOTUM (0.37) | NOTUMHTR2AHTR2C | |
| SCHEMBL4500824 | 0.67 | HTR2A (0.34) | NOTUMHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096595-B2 | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045870-A1 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGDR2, PTGER1 | NOTUM 2699/4885HTR2A 57/4885HTR2C 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.